Editorial: Targeting metabolism to activate T cells and enhance the efficacy of checkpoint blockade immunotherapy in solid tumors.
作者信息
Xia Zhijia, Chen Shi, He Miao, Li Benhua, Deng Yayuan, Yi Lin, Li Xiaosong
机构信息
Department of General, Visceral, and Transplant Surgery, Ludwig-Maximilians-University Munich, Munich, Germany.
Clinical Molecular Medicine Testing Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
出版信息
Front Immunol. 2023 Jul 27;14:1247178. doi: 10.3389/fimmu.2023.1247178. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Targeting metabolism to activate T cells and enhance the efficacy of checkpoint blockade immunotherapy in solid tumors.
Front Immunol. 2023 Jul 27;14:1247178. doi: 10.3389/fimmu.2023.1247178. eCollection 2023.
2
Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
Cell Commun Signal. 2020 Sep 7;18(1):142. doi: 10.1186/s12964-020-00638-2.
3
IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors.
Mol Ther. 2020 Nov 4;28(11):2379-2393. doi: 10.1016/j.ymthe.2020.07.018. Epub 2020 Jul 21.
4
Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy.
Front Immunol. 2022 Dec 7;13:1046755. doi: 10.3389/fimmu.2022.1046755. eCollection 2022.
5
The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy.
Curr Drug Targets. 2021;22(9):1021-1033. doi: 10.2174/1389450122666210204204415.
6
Alternative Checkpoints as Targets for Immunotherapy.
Curr Oncol Rep. 2020 Nov 3;22(12):126. doi: 10.1007/s11912-020-00983-y.
7
Targeting immune checkpoints in hematological malignancies.
J Hematol Oncol. 2020 Aug 12;13(1):111. doi: 10.1186/s13045-020-00947-6.
8
Nanobodies targeting immune checkpoint molecules for tumor immunotherapy and immunoimaging (Review).
Int J Mol Med. 2021 Feb;47(2):444-454. doi: 10.3892/ijmm.2020.4817. Epub 2020 Dec 14.
9
Thymic Function and T-Cell Receptor Repertoire Diversity: Implications for Patient Response to Checkpoint Blockade Immunotherapy.
Front Immunol. 2021 Nov 24;12:752042. doi: 10.3389/fimmu.2021.752042. eCollection 2021.
10
CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells.
Cancer Discov. 2021 Aug;11(8):2050-2071. doi: 10.1158/2159-8290.CD-20-1144. Epub 2021 Mar 11.
引用本文的文献
1
Roles and functions of tumor-infiltrating lymphocytes and tertiary lymphoid structures in gastric cancer progression.
Front Immunol. 2025 May 29;16:1595070. doi: 10.3389/fimmu.2025.1595070. eCollection 2025.
2
Immunosuppressive tumor microenvironment in pancreatic cancer: mechanisms and therapeutic targets.
Front Immunol. 2025 May 15;16:1582305. doi: 10.3389/fimmu.2025.1582305. eCollection 2025.
3
Immunotherapeutic strategies for invasive bladder cancer: a comprehensive review.
Front Immunol. 2025 Apr 30;16:1591379. doi: 10.3389/fimmu.2025.1591379. eCollection 2025.
4
Metabolic reprogramming and immune microenvironment characteristics in laryngeal carcinoma: advances in immunotherapy.
Front Immunol. 2025 Apr 30;16:1589243. doi: 10.3389/fimmu.2025.1589243. eCollection 2025.
5
Metabolic reprogramming in hepatocellular carcinoma: mechanisms of immune evasion and therapeutic implications.
Front Immunol. 2025 Apr 30;16:1592837. doi: 10.3389/fimmu.2025.1592837. eCollection 2025.
6
The malignant signature gene of cancer-associated fibroblasts serves as a potential prognostic biomarker for colon adenocarcinoma patients.
Front Immunol. 2025 Apr 17;16:1589678. doi: 10.3389/fimmu.2025.1589678. eCollection 2025.
7
The role of Treg cells in colorectal cancer and the immunotherapy targeting Treg cells.
Front Immunol. 2025 Apr 16;16:1574327. doi: 10.3389/fimmu.2025.1574327. eCollection 2025.
8
Causal association between immune cell phenotypes and colorectal cancer: a two-sample bidirectional Mendelian randomization analysis.
Discov Oncol. 2025 Apr 29;16(1):638. doi: 10.1007/s12672-025-02443-0.
9
Acute aerobic exercise alters serum protein distribution in colorectal cancer patients.
Front Oncol. 2025 Apr 9;15:1586344. doi: 10.3389/fonc.2025.1586344. eCollection 2025.
10
The role of tumor-associated macrophages in HPV induced cervical cancer.
Front Immunol. 2025 Apr 8;16:1586806. doi: 10.3389/fimmu.2025.1586806. eCollection 2025.
本文引用的文献
1
A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts.
Front Immunol. 2023 May 31;14:1201573. doi: 10.3389/fimmu.2023.1201573. eCollection 2023.
2
Metabolic reprogramming of cancer-associated fibroblasts in pancreatic cancer contributes to the intratumor heterogeneity of PET-CT.
Comput Struct Biotechnol J. 2023 Apr 7;21:2631-2639. doi: 10.1016/j.csbj.2023.04.003. eCollection 2023.
3
Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma.
Front Immunol. 2023 Mar 17;14:1153423. doi: 10.3389/fimmu.2023.1153423. eCollection 2023.
4
Metabolic plasticity and regulation of T cell exhaustion.
Immunology. 2022 Dec;167(4):482-494. doi: 10.1111/imm.13575. Epub 2022 Sep 30.
5
Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells.
J Hematol Oncol. 2022 Mar 28;15(1):38. doi: 10.1186/s13045-022-01255-x.
6
Prosurvival IL-7-Stimulated Weak Strength of mTORC1-S6K Controls T Cell Memory via Transcriptional FOXO1-TCF1-Id3 and Metabolic AMPKα1-ULK1-ATG7 Pathways.
J Immunol. 2022 Jan 1;208(1):155-168. doi: 10.4049/jimmunol.2100452. Epub 2021 Dec 6.
7
The Importance of Cellular Metabolic Pathways in Pathogenesis and Selective Treatments of Hematological Malignancies.
Front Oncol. 2021 Nov 10;11:767026. doi: 10.3389/fonc.2021.767026. eCollection 2021.
8
IL-33 activates mTORC1 and modulates glycolytic metabolism in CD8 T cells.
Immunology. 2022 Jan;165(1):61-73. doi: 10.1111/imm.13404. Epub 2021 Aug 31.
9
Interleukin-34 Reprograms Glycolytic and Osteoclastic Rheumatoid Arthritis Macrophages via Syndecan 1 and Macrophage Colony-Stimulating Factor Receptor.
Arthritis Rheumatol. 2021 Nov;73(11):2003-2014. doi: 10.1002/art.41792. Epub 2021 Sep 22.
10
IL-23 and IL-1β Drive Human Th17 Cell Differentiation and Metabolic Reprogramming in Absence of CD28 Costimulation.
Cell Rep. 2018 Mar 6;22(10):2642-2653. doi: 10.1016/j.celrep.2018.02.044.
Zotero 插件